Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00814827
First received: December 24, 2008
Last updated: July 18, 2014
Last verified: June 2014

December 24, 2008
July 18, 2014
December 2008
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00814827 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

Opportunistic infections are caused by bacteria, mycobacteria, fungi or viruses that do not normally cause infections in people with healthy immune systems. Some of these infections can cause public health concerns, especially in areas with limited access to treatment. People who acquire opportunistic infections usually have diseases that affect their immune systems, such as human immunodeficiency virus (HIV), or do not have enough white blood cells to fight the infection. However, some people acquire opportunistic infections even though they have normal amounts of white blood cells and are free from known diseases that harm their immune systems. This study will investigate some of the reasons that otherwise healthy people get opportunistic infections to learn more about why some people are more likely to have them.

This study will include up to 210 HIV-negative males and females older than 18 years of age who have opportunistic infections. The patients will be drawn from multiple sites in Thailand and Taiwan including Khon Kaen University Hospital, Siriraj Hospital, Ramathibodi Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital

Patients will undergo an initial evaluation that will include a physical examination, medical history, and blood and urine testing. Additional tests will be conducted if the researchers consider that the tests are medically necessary to treat the opportunistic infection; the results of the tests will be reviewed and saved for study purposes. Depending on the severity of the infection, the initial evaluation may take more than 1 day to complete.

After the evaluation, patients will be given standard and appropriate medicines to treat the infections.

Patients will return for follow-up visits to allow researchers to monitor their condition and to assess how well the patient is responding to the treatment. Patients will be evaluated by the study researchers at least once a year for 2 years following the initial treatment.

The acquisition of opportunistic infections has been causally linked to innate and acquired immunodeficiencies. We have recently identified a population of Asian women with autoantibodies to interferon gamma (IFN?), all of whom were diagnosed by virtue of nontuberculous mycobacterial infections. Similar patient populations have been reported from Thailand, and we have found similar autoantibodies in anonymous serum samples from there. In addition, many of the Thai patients who have disseminated or lymphatic nontuberculous infections have had other opportunistic infections (OI), such as salmonella, penicilliosis, and histoplasmosis. However, they have normal lymphocyte counts and are human immunodeficiency virus (HIV) negative. Therefore, the identification of autoantibodies to a critical cytokine, the occurrence of opportunistic infections, and the lack of other common explanations suggests that this is an important population to study. We propose to enroll patients in a natural history study of non-HIV opportunistic infections to explore the presence of autoantibodies to cytokines, and to examine potential immunogenetic factors influencing the development of this disease. Plasma, cells, and DNA samples will be obtained and stored for use in this study. This study will accrue up to 210 patients over 3 years as per the groups described in section 4.3

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Immunodeficiency
  • Mycobacterial Infection
  • Opportunistic Infection
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
265
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Patients must meet all of the following criteria at the time of evaluation to be eligible for enrollment into the study cohorts:

Group 1 (NTM alone):

  1. Past or current infection with NTM proven by culture or specific DNA detection in the presence of a compatible clinical picture as judged by the responsible clinician and PI on site.
  2. NTM is not felt to iatrogenic (such as indwelling catheter associated or post-operative wound infection)
  3. HIV negative within 3 months either prior to the diagnosis of OI, or prior to enrollment in this study, if HIV status was unknown at the time of OI
  4. No evidence of active malignancy
  5. No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4 weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
  6. No preexisting immune deficiency

Group 2 (non-NTM OI with or without NTM):

  1. Patients must have or have had proven infection with one or more of the following organisms: disseminated Salmonella, Listeria, Penicillium, Burkholderia pseudomallei, Cryptococcus, Histoplasma, Herpes zoster involving 2 or more non-contiguous dermatomes, or extradermal involvement or other opportunistic infections not listed above, but relevant, as determined by the PI.
  2. Patient may have infection with NTM in addition to one or more of the above infection(s).
  3. HIV-negative within 3 months either prior to the diagnosis of OI, or prior to enrollment in this study, if HIV status was unknown at the time of OI diagnosis
  4. No evidence of active malignancy
  5. No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4 weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
  6. No preexisting immune deficiency

Group 3 (diseased control with pulmonary MTB):

  1. Active pulmonary MTB, i.e. patients who have sputum that is either culture positive for MTB or AFB positive and responding to therapy for MTB.
  2. Diagnosed with the past 6 months.
  3. No concurrent infections due to NTM or OI listed under above inclusion criteria for study subjects
  4. No clinical evidence of HIV

Group 4 (diseased control with disseminated MTB):

Disseminated MTB includes infections involving greater than or equal to 2 noncontiguous sites, one of which may include pulmonary disease or greater than or equal to 2 separate groups of lymph nodes.

  1. Active disseminated MTB or cured disseminated MTB
  2. No concurrent infections due to NTM or OI listed under above inclusion criteria for study subjects
  3. HIV negative within 3 months either prior to the diagnosis of MTB, or prior to enrollment in this study, if HIV status was unknown at the time of MTB diagnosis
  4. No evidence of active malignancy
  5. No systemic corticosteroids at time of diagnosis of OI (defined as > 4 weeks at a dose > 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
  6. No preexisting immune deficiency.

Group 5 (Blood Specimen Donors):

Eligibility criteria not applicable. Blood will be collected from volunteers, and no medical evaluation will be performed.

To be a blood donor the person cannot be excluded per the exclusionary criteria:

  1. Patient < 18 or > 85
  2. Weight > 45 kg (99 lbs)
  3. Receiving chemotherapy of have cancer
  4. Receiving immunosuppressant medications
  5. Have a history of heart, lung, kidney disease of bleeding disorder.

EXCLUSION CRITERIA:

Patients will be excluded for the following reasons:

  1. HIV-positive serostatus for groups 1, 2 and 4 (groups 3 and 5 will not be routinely performing HIV testing)
  2. Active malignancy
  3. Medical conditions requiring immune modulating therapy (i.e. corticosteroids, biological agents, anti-metabolites) and /or chemotherapy
  4. Any other medical conditions unsuitable for this study as determined by the principal investigator
  5. Age less than 18 years
  6. Receiving any other investigational study agents when enrolling on this study.
Both
18 Years to 85 Years
No
Contact: Reginald J Claypool, R.N. (301) 402-7831 rclaypool@niaid.nih.gov
Contact: Christa S Zerbe, M.D. (301) 594-5932 zerbech@niaid.nih.gov
Thailand
 
NCT00814827
999909060, 09-I-N060
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Christa S Zerbe, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP